NRx Pharmaceuticals, Inc
Price
FilingsNewest: 8-K, Material agreementOct 5 →InsidersNo open-market buys or sales.→HoldersB Group 9.5%Vanguard 3.7%Ameriprise Financial 2.2%→PeersClosest companies: RLMD, CING, CVKD→
From the filings
Figures
- Revenue
- $3.4Mlast 12 months
- Net income
- −$23.5Mlast 12 months
- Operating cash flow
- −$14.9Mlast 12 months
- Cash and equivalents
- $26.7Mat the last balance sheet
- Shares outstanding
- 43.2M shareson issue